NCT00743977Unknown不适用
2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine
研究概览
简要总结
The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic product.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects aged 18 to 55 (Male & Female)
- •Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests
- •Informed consent signed by the subject
- •The subject is co-operative and available for the entire study
- •Not pregnant or nursing
- •Normal renal and hepatic function
排除标准
- •Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation
- •Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma
- •Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg)
- •Evidence of chronic or acute infectious diseases;
- •History or evidence of malignant tumors;
- •Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl)
- •Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl)
- •Planned vaccination during the time course of the study
- •Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation
- •Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing
- •Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)
- •Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study
- •Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)
- •Drug addiction
- •Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week
- •Subjects who are known or suspected
- •not to comply with the study directives
- •not to be reliable or trustworthy
- •not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed.
- •to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.
研究组 & 干预措施
A
Active Comparator
干预措施: Phenazopyridine HCl (Drug)
B
Experimental
干预措施: Phenazopyridine HCl (Drug)
结局指标
主要结局
The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine
时间窗: regular intervals after drug dosing
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
Unknown
Bioequivalence study of Phenazopyridine 100mg tabletThis study is performed on healthy volunteers..IRCT20200623047902N31Ronak Pharm company24
已完成
3 期
Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. PlaceboPainUrinary Tract InfectionsNCT01064024Amneal Pharmaceuticals, LLC233
招募中
Unknown
Bioequivalence study of phenazopyridine hydrochloride 100 mg tablet---.IRCT20230222057495N11Mehr Darou Pharmaceutical Company24
已完成
3 期
Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)Uncomplicated Urinary Tract InfectionsNCT01650051Amneal Pharmaceuticals, LLC424
已完成
1 期
Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.Asthma,Pharmacokinetics,Cmax,Tmax,λz,AUC,Ketoconazole,MetaboliteNCT01735240AstraZeneca15